Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

Completed · Not applicable

Conditions studied: Acne Vulgaris

In brief

Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris

Key facts

Study ID

NCT03303170

Run by

Sebacia, Inc.

People needed

168

Starts

2017-09-25

Expected to finish

2018-04-10

Last updated by the study team

2019-10-14

Who can join

Age: 12 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate acne vulgaris
• At least 15 inflammatory acne lesions
• Skin phototype I - III
• Able to understand and comply with study requirements

You may not qualify if…

• Severe acne vulgaris
• Nodulocystic acne
• Ongoing use of medications and/or treatments for acne
• New hormone regimen (used for less than 12 weeks)
• Significant medical or mental health condition

Where it is running

• Clear Dermatology & Aesthetics Center — Scottsdale, Arizona, United States
• Scripps Health — San Diego, California, United States
• Miami Dermatology & Laser Institute — Miami, Florida, United States
• Meridian Clinical Research — Savannah, Georgia, United States
• MediSearch Clinical Trials — Saint Joseph, Missouri, United States
• Dermatology, Laser & Vein Institute — Charlotte, North Carolina, United States
• Wake Research Associates — Raleigh, North Carolina, United States
• International Clinical Research — Murfreesboro, Tennessee, United States
• Austin Institute for Clinical Research — Austin, Texas, United States
• The Center for Skin Research — Katy, Texas, United States
• Premier Clinical Research — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.